Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

About Ligand Pharmaceuticals

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LGND
  • CUSIP: 53220K50
Key Metrics:
  • Previous Close: $93.51
  • 50 Day Moving Average: $105.62
  • 200 Day Moving Average: $116.29
  • 52-Week Range: $82.06 - $139.79
  • Trailing P/E Ratio: 8.82
  • Foreward P/E Ratio: 18.70
  • P/E Growth: 0.65
  • Market Cap: $1.95B
  • Outstanding Shares: 20,854,000
  • Beta: 1.23
  • Net Margins: 263.14%
  • Return on Equity: 11.64%
  • Return on Assets: 7.03%
  • Current Ratio: 0.57%
  • Quick Ratio: 0.56%
Additional Links:
Companies Related to Ligand Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $141.43 (51.24% upside)

Analysts' Ratings History for Ligand Pharmaceuticals (NASDAQ:LGND)
DateFirmActionRatingPrice TargetDetails
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00View Rating Details
10/5/2016Craig HallumBoost Price Target$150.00 -> $160.00View Rating Details
10/5/2016HC WainwrightReiterated RatingBuy$146.00 -> $160.00View Rating Details
9/28/2016Roth CapitalReiterated RatingBuy$151.00 -> $150.00View Rating Details
9/7/2016Deutsche Bank AGUpgradeSell -> Hold$110.00 -> $105.00View Rating Details
4/13/2016StephensInitiated CoverageOverweight$150.00View Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00View Rating Details
6/19/2015Cantor FitzgeraldBoost Price TargetHold$86.00 -> $93.00View Rating Details
3/3/2015CRT CapitalInitiated CoverageBuy$102.00View Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Ligand Pharmaceuticals (NASDAQ:LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.65$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.81$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.27$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.60$0.60$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.31$0.36$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ligand Pharmaceuticals (NASDAQ:LGND)
Current Year EPS Consensus Estimate: $3.44 EPS
Next Year EPS Consensus Estimate: $5.00 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.44$0.46$0.45
Q2 20161$0.54$0.54$0.54
Q3 20163$0.06$0.63$0.44
Q4 20163$0.69$1.16$0.98
(Data provided by Zacks Investment Research)


Dividend History for Ligand Pharmaceuticals (NASDAQ:LGND)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ligand Pharmaceuticals (NASDAQ:LGND)
Insider Ownership Percentage: 14.70%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.00View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.40View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ligand Pharmaceuticals (NASDAQ:LGND)
News IconRating Sentiment Worth Watching: This is what analysts have to say ... - MoneyMakingArticles (NASDAQ:LGND) - October 21 at 9:19 AM
News IconSEC Filing: Ligand Pharmaceuticals INC (LGND) Shareholder Cardinal Capital Management LLC Has Trimmed Its ... - Chester News (NASDAQ:LGND) - October 20 at 11:37 AM
News Icon3807 Shares of Ligand Pharmaceuticals Inc. (LGND) are sold by First Citizens Bank & Trust Co. - DailyQuint (NASDAQ:LGND) - October 16 at 10:23 AM
News IconLigand Pharmaceuticals (LGND) – Analysts' Recent Ratings ... - DailyQuint (NASDAQ:LGND) - October 15 at 5:36 PM logoLigand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference (NASDAQ:LGND) - October 13 at 9:27 AM
News IconHolder Worth Mentioning: Ligand Pharmaceuticals INC (LGND) Shareholder Turner Investments LP Raised Holding by ... - Chester News (NASDAQ:LGND) - October 12 at 11:06 AM logoFDA Says No To Nicox, Lundbeck's Persistence Pays Off, It's A Win For LPCN (NASDAQ:LGND) - October 10 at 10:34 AM logoLigand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types (NASDAQ:LGND) - October 8 at 10:25 AM
News IconH.C. Wainwright Reaffirms $160.0 TP On Ligand Pharma (NASDAQ:LGND), Reaffirms "Buy" Rating - Thorold News (NASDAQ:LGND) - October 7 at 5:42 PM logoIs It Too Late to Get In on This Millionaire-Maker Stock? (NASDAQ:LGND) - September 30 at 10:22 AM logoLigand Pharmaceuticals Enters Oversold Territory (LGND) (NASDAQ:LGND) - September 27 at 5:50 PM logoHere's Why Ligand Pharmaceuticals Inc Is Plunging Today (NASDAQ:LGND) - September 27 at 4:27 PM logoAnalysts Forecast 14% Upside For IYH (NASDAQ:LGND) - September 27 at 10:31 AM logoRegeneron, Sanofi Skin Disease Drug Under Priority Review (NASDAQ:LGND) - September 26 at 5:57 PM logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : September 26, 2016 (NASDAQ:LGND) - September 26 at 10:33 AM logoLigand Pharmaceuticals : Blue Clay Capital Management Lowers stake in Ligand Pharmaceuticals (LGND) (NASDAQ:LGND) - September 25 at 5:17 PM logoLigand Pharmaceuticals : Pharma (LGND) Enters Licensing Agreements with Seelos Therapeutics for Four Programs (NASDAQ:LGND) - September 24 at 5:26 PM logoLigand Pharma (LGND) Enters Licensing Agreements with Seelos Therapeutics for Four Programs - (NASDAQ:LGND) - September 23 at 5:35 PM logoLigand Inks CNS License Agreement with Seelos Therapeutics (NASDAQ:LGND) - September 23 at 10:39 AM logoLigand Pharma (LGND) Enters Licensing Agreements with Seelos Therapeutics for Four Programs (NASDAQ:LGND) - September 22 at 5:42 PM logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:LGND) - September 22 at 5:42 PM logoLigand Licenses Four Programs to Seelos Therapeutics (NASDAQ:LGND) - September 22 at 9:07 AM logoLigand (LGND) Inks Deal with TeneoBio for OmniAb Technology - Yahoo Finance (NASDAQ:LGND) - September 20 at 11:04 AM logoLigand (LGND) Inks Deal with TeneoBio for OmniAb Technology (NASDAQ:LGND) - September 19 at 10:27 AM logoETF’s with exposure to Ligand Pharmaceuticals, Inc. : September 19, 2016 (NASDAQ:LGND) - September 19 at 10:27 AM logoLigand Enters OmniAb® License Agreement with TeneoBio, Inc. (NASDAQ:LGND) - September 16 at 11:31 AM logoCommit To Purchase Ligand Pharmaceuticals At $100, Earn 10.8% Annualized Using Options (NASDAQ:LGND) - September 15 at 9:01 PM
News IconLigand Pharmaceuticals Inc. Can't Burn Your Long Portfolio. Has Another Strong Session - Chester News (NASDAQ:LGND) - September 15 at 3:53 PM logoCommit To Purchase Ligand Pharmaceuticals At $100, Earn 10.8% Annualized Using Options - Nasdaq (NASDAQ:LGND) - September 15 at 3:53 PM
News IconLigand (LGND) Commences Phase II Type II Diabetes Study - Yahoo Sports (NASDAQ:LGND) - September 14 at 6:00 PM logoLigand Pharma Initiates Phase 2 Trial For LGD-6972 - Quick Facts (NASDAQ:LGND) - September 14 at 10:08 AM logoLigand (LGND) Commences Phase II Type II Diabetes Study (NASDAQ:LGND) - September 14 at 10:08 AM logoLigand Pharma initiates Phase 2 trial for LGD-6972 - Quick Facts - RTT News (NASDAQ:LGND) - September 13 at 10:44 AM logoSpectra Energy Corp (NYSE:SE), Ligand Pharmaceuticals ... - Benzinga (NASDAQ:LGND) - September 8 at 9:48 AM logoLigand Pharma (LGND) Says Retrophin (RTRX) Presented Sparsentan Phase 2 Study Data - (NASDAQ:LGND) - September 8 at 9:48 AM logoAnalyst Update: Applied Optoelectronics Inc, Ligand ... - Schaeffers Research (blog) (NASDAQ:LGND) - September 8 at 9:48 AM logoLGND Makes Bullish Cross Above Critical Moving Average (NASDAQ:LGND) - September 7 at 6:03 PM logoAnalyst Update: Applied Optoelectronics Inc, Ligand Pharmaceuticals Inc., and Momenta Pharmaceuticals, Inc. (NASDAQ:LGND) - September 7 at 6:03 PM logo9:27 am Ligand Pharma: Retrophin (RTRX (NASDAQ:LGND) - September 7 at 6:03 PM logoWhy Shares of Retrophin Inc Are Soaring Today (NASDAQ:LGND) - September 7 at 6:03 PM logoRetrophin, Ligand Pharma Jump As Rare-Disease Drug Hits In Trial (NASDAQ:LGND) - September 7 at 6:03 PM logoLigand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis (NASDAQ:LGND) - September 7 at 9:28 AM logoLigand to Participate in Two Upcoming Investor Conferences (NASDAQ:LGND) - September 2 at 10:45 AM logoIntec Pharma reports Q2 results (NASDAQ:LGND) - September 1 at 8:59 AM logoStocks in Focus: Ligand Pharmaceuticals Incorporated (NASDAQ ... - KC Register (NASDAQ:LGND) - August 26 at 5:45 PM
News IconLigand Pharmaceuticals Inc. (NASDAQ:LGND) Analyst Opinion - The Independent Republic (NASDAQ:LGND) - August 26 at 5:45 PM logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements an (NASDAQ:LGND) - August 26 at 8:57 AM logoRough Month: A Closer Look At Ligand's Fall From All-Time Highs (NASDAQ:LGND) - August 24 at 5:48 PM logoETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 24, 2016 (NASDAQ:LGND) - August 24 at 5:48 PM logoThese 3 Stocks Are Up Over 700% in the Last 5 Years (NASDAQ:LGND) - August 23 at 6:08 PM


Ligand Pharmaceuticals (NASDAQ:LGND) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff